<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>IUIS classification of complement deficiencies (category VIII inborn errors of immunity)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">IUIS classification of complement deficiencies (category VIII inborn errors of immunity)</h1>
<div class="graphic"><div class="figure"><div class="ttl">IUIS classification of complement deficiencies (category VIII inborn errors of immunity)</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16.6%"></colgroup> <tbody> <tr> <td class="subtitle1">Disease</td> <td class="subtitle1">Genetic defect</td> <td class="subtitle1">Inheritance</td> <td class="subtitle1">OMIM</td> <td class="subtitle1">Laboratory features</td> <td class="subtitle1">Associated features</td> </tr> <tr> <td rowspan="3">C1q deficiency due to defects</td> <td>Complement C1q A chain (<em>C1QA</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/120550" target="_blank">120550</a></td> <td>Absent CH50 hemolytic activity, defective activation of the classical pathway, diminished clearance of apoptotic cells</td> <td>SLE, infections with encapsulated organisms</td> </tr> <tr> <td>Complement C1q B chain (<em>C1QB</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/120570" target="_blank">120570</a></td> <td>Absent CH50 hemolytic activity, defective activation of the classical pathway, diminished clearance of apoptotic cells</td> <td>SLE, infections with encapsulated organisms</td> </tr> <tr> <td>Complement C1q C chain (<em>C1QC</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/120575" target="_blank">120575</a></td> <td>Absent CH50 hemolytic activity, defective activation of the classical pathway, diminished clearance of apoptotic cells</td> <td>SLE, infections with encapsulated organisms</td> </tr> <tr> <td>C1r deficiency</td> <td>Complement C1r (<em>C1R</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/613785" target="_blank">613785</a></td> <td>Absent CH50 hemolytic activity, defective activation of the classical pathway</td> <td>SLE, infections with encapsulated organisms, Ehlers-Danlos phenotype</td> </tr> <tr> <td>C1r periodontal Ehlers-Danlos</td> <td>Complement C1r (<em>C1R</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/613785" target="_blank">613785</a></td> <td>Normal CH50</td> <td>Hyperpigmentation, skin fragility</td> </tr> <tr> <td>C1s deficiency</td> <td>Complement C1s (<em>C1S</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/613785" target="_blank">613785</a></td> <td>Absent CH50 hemolytic activity, defective activation of the classical pathway</td> <td>SLE, infections with encapsuled organisms, Ehlers-Danlos phenotype</td> </tr> <tr> <td>C1s periodontal Ehlers-Danlos</td> <td>Complement C1s (<em>C1S</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/613785" target="_blank">613785</a></td> <td>Normal CH50</td> <td>Hyperpigmentation, skin fragility</td> </tr> <tr> <td>Complete C4 deficiency</td> <td>Complement C4A (Rodgers blood group; <em>C4A</em>) + complement C4B (Chido blood group; <em>C4B</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/120810" target="_blank">120810</a></td> <td>Absent CH50 hemolytic activity, defective activation of the classical pathway, complete deficiency requires biallelic mutations/deletions/conversions of both <em>C4A</em> and <em>C4B</em></td> <td>SLE, infections with encapsulated organisms, partial deficiency is common (either <em>C4A</em> or <em>C4B</em>) and appears to have a modest effect on host defense</td> </tr> <tr> <td>C2 deficiency</td> <td>Complement C2 (<em>C2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/217000" target="_blank">217000</a></td> <td>Absent CH50 hemolytic activity, defective activation of the classical pathway</td> <td>SLE, infections with encapsulated organisms, atherosclerosis</td> </tr> <tr> <td>C3 deficiency (LOF)</td> <td>Complement C3 (<em>C3</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/120700" target="_blank">120700</a></td> <td>Absent CH50 and AH50 hemolytic activity, defective opsonization, defective humoral immune response</td> <td>Infections, glomerulonephritis, aHUS, with GOF mutation</td> </tr> <tr> <td>C3 GOF</td> <td>Complement C3 (<em>C3</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/120700" target="_blank">120700</a></td> <td>Increased activation of complement</td> <td>aHUS</td> </tr> <tr> <td>C5 deficiency</td> <td>Complement C5 (<em>C5</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/120900" target="_blank">120900</a></td> <td>Absent CH50 and AH50 hemolytic activity, defective bactericidal activity</td> <td>Disseminated neisserial infections</td> </tr> <tr> <td>C6 deficiency</td> <td>Complement C6 (<em>C6</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/217050" target="_blank">217050</a></td> <td>Absent CH50 and AH50 hemolytic activity, defective bactericidal activity</td> <td>Disseminated neisserial infections</td> </tr> <tr> <td>C7 deficiency</td> <td>Complement C7 (<em>C7</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/217070" target="_blank">217070</a></td> <td>Absent CH50 and AH50 hemolytic activity, defective bactericidal activity</td> <td>Disseminated neisserial infections</td> </tr> <tr> <td>C8 alpha deficiency</td> <td>Complement C8 alpha chain (<em>C8A</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/120950" target="_blank">120950</a></td> <td>Absent CH50 and AH50 hemolytic activity, defective bactericidal activity</td> <td>Disseminated neisserial infections</td> </tr> <tr> <td>C8 gamma deficiency</td> <td>Complement C8 gamma chain (<em>C8G</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/120930" target="_blank">120930</a></td> <td>Absent CH50 and AH50 hemolytic activity, defective bactericidal activity</td> <td>Disseminated neisserial infections</td> </tr> <tr> <td>C8 beta deficiency</td> <td>Complement C8 beta chain (<em>C8B</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/120960" target="_blank">120960</a></td> <td>Absent CH50 and AH50 hemolytic activity, defective bactericidal activity</td> <td>Disseminated neisserial infections</td> </tr> <tr> <td>C9 deficiency</td> <td>Complement C9 (<em>C9</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/120940" target="_blank">120940</a></td> <td>Reduced CH50 and AP50 hemolytic activity, deficient bactericidal activity</td> <td>Mild susceptibility to disseminated neisserial infections</td> </tr> <tr> <td>MASP2 deficiency</td> <td>MBL-associated serine protease 2 (<em>MASP2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/605102" target="_blank">605102</a></td> <td>Deficient activation of the lectin activation pathway</td> <td>Pyogenic infections, inflammatory lung disease, autoimmunity</td> </tr> <tr> <td>Ficolin 3 deficiency</td> <td>Ficolin 3 (<em>FCN3</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/604973" target="_blank">604973</a></td> <td>Absence of complement activation by the ficolin 3 pathway</td> <td>Respiratory infections, abscesses</td> </tr> <tr> <td>C1 inhibitor deficiency</td> <td>Serpin family G member 1 (<em>SERPING1</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/606860" target="_blank">606860</a></td> <td>Spontaneous activation of the complement pathway with consumption of C4/C2, spontaneous activation of the contact system with generation of bradykinin from high-molecular-weight kininogen</td> <td>Hereditary angioedema</td> </tr> <tr> <td>Factor B GOF</td> <td>Complement factor B (<em>CFB</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/612924" target="_blank">612924</a></td> <td>GOF mutation with increased spontaneous AH50</td> <td>aHUS</td> </tr> <tr> <td>Factor B deficiency</td> <td>Complement factor B (<em>CFB</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/615561" target="_blank">615561</a></td> <td>Deficient activation of the alternative pathway</td> <td>Infections with encapsulated organisms</td> </tr> <tr> <td>Factor D deficiency</td> <td>Complement factor D (<em>CFD</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/134350" target="_blank">134350</a></td> <td>Absent AH50 hemolytic activity</td> <td>Neisserial infections</td> </tr> <tr> <td>Properdin deficiency</td> <td>Complement factor properdin (<em>CFP</em>)</td> <td>XL</td> <td><a href="https://www.omim.org/entry/300383" target="_blank">300383</a></td> <td>Absent AH50 hemolytic activity</td> <td>Neisserial infections</td> </tr> <tr> <td>Factor I deficiency</td> <td>Complement factor I (<em>CFI</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/217030" target="_blank">217030</a></td> <td>Spontaneous activation of the alternative complement pathway with consumption of C3</td> <td>Infections, disseminated neisserial infections, aHUS, preeclampsia</td> </tr> <tr> <td>Factor H deficiency</td> <td>Complement factor H (<em>CFH</em>)</td> <td>AR or AD</td> <td><a href="https://www.omim.org/entry/134370" target="_blank">134370</a></td> <td>Spontaneous activation of the alternative complement pathway with consumption of C3</td> <td>Infections, disseminated neisserial infections, aHUS, preeclampsia</td> </tr> <tr> <td rowspan="5">Factor H-related protein deficiencies</td> <td>Complement factor H-related 1 (<em>CFHR1</em>)</td> <td>AR or AD</td> <td><a href="https://www.omim.org/entry/134371" target="_blank">134371</a></td> <td>Normal CH50 and AH50, autoantibodies to factor H, linked deletions of one or more CFHR genes leads to susceptibility to autoantibody-mediated aHUS</td> <td>Older-onset aHUS, disseminated neisserial infections</td> </tr> <tr> <td>Complement factor H-related 2 (<em>CFHR2</em>)</td> <td>AR or AD</td> <td><a href="https://www.omim.org/entry/600889" target="_blank">600889</a></td> <td>Normal CH50 and AH50, autoantibodies to factor H, linked deletions of one or more CFHR genes leads to susceptibility to autoantibody-mediated aHUS</td> <td>Older-onset aHUS, disseminated neisserial infections</td> </tr> <tr> <td>Complement factor H-related 3 (<em>CFHR3</em>)</td> <td>AR or AD</td> <td><a href="https://www.omim.org/entry/605336" target="_blank">605336</a></td> <td>Normal CH50 and AH50, autoantibodies to factor H, linked deletions of one or more CFHR genes leads to susceptibility to autoantibody-mediated aHUS</td> <td>Older-onset aHUS, disseminated neisserial infections</td> </tr> <tr> <td>Complement factor H-related 4 (<em>CFHR4</em>)</td> <td>AR or AD</td> <td><a href="https://www.omim.org/entry/605337" target="_blank">605337</a></td> <td>Normal CH50 and AH50, autoantibodies to factor H, linked deletions of one or more CFHR genes leads to susceptibility to autoantibody-mediated aHUS</td> <td>Older-onset aHUS, disseminated neisserial infections</td> </tr> <tr> <td>Complement factor H-related 5 (<em>CFHR5</em>)</td> <td>AR or AD</td> <td><a href="https://www.omim.org/entry/608593" target="_blank">608593</a></td> <td>Normal CH50 and AH50, autoantibodies to factor H, linked deletions of one or more CFHR genes leads to susceptibility to autoantibody-mediated aHUS</td> <td>Older-onset aHUS, disseminated neisserial infections</td> </tr> <tr> <td>Thrombomodulin deficiency</td> <td>Thrombomodulin (<em>THBD</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/188040" target="_blank">188040</a></td> <td>Normal CH50 and AH50</td> <td>aHUS</td> </tr> <tr> <td>Membrane cofactor protein (CD46) deficiency</td> <td>CD46 molecule (<em>CD46</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/120920" target="_blank">120920</a></td> <td>Inhibitor of complement alternate pathway, decreased C3b binding</td> <td>aHUS, infections, preeclampsia</td> </tr> <tr> <td>Membrane attack complex inhibitor (CD59) deficiency</td> <td>CD59 molecule (CD59 blood group; <em>CD59</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/107271" target="_blank">107271</a></td> <td>Erythrocytes highly susceptible to complement-mediated lysis</td> <td>Hemolytic anemia, polyneuropathy</td> </tr> <tr> <td>CD55 deficiency (CHAPLE disease)</td> <td>CD55 molecule (Cromer blood group; <em>CD55</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/125240" target="_blank">125240</a></td> <td>Hyperactivation of complement on endothelium</td> <td>Protein-losing enteropathy, thrombosis</td> </tr> </tbody></table></div><div class="graphic_lgnd">Total number of mutant genes in table: 36.</div><div class="graphic_footnotes">IUIS: International Union of Immunological Societies; 
    AR: autosomal recessive; 
    CH50: total hemolytic complement; 
    SLE: systemic lupus erythematosus; 
    AD: autosomal dominant; 
    GOF: gain of function; 
    LOF: loss of function; 
    AH50: alternative complement; 
    aHUS: atypical hemolytic-uremic syndrome; 
    XL: X linked; 
    CD: cluster of differentiation; 
    CHAPLE: CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and severe protein-losing enteropathy.</div><div class="graphic_reference">From: Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2022; 42:1473. Copyright Â© 2022 The Authors. Reproduced under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License 4.0</a>.</div><div id="graphicVersion">Graphic 140080 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
